Professor Ngs research contributions to AOD-9604 development include: Synthesis and characterization of the modified C-terminal growth hormone fragment with enhanced stability Design of the tyrosine N-terminal modification to improve peptide stability and half-life Preclinical studies demonstrating lipolytic effects in obese animal models Advancement of the peptide through multiple phases of clinical development Investigation of mechanisms underlying beta-3-adrenergic receptor modulation His work established the foundation for understanding peptide-based approaches to metabolic regulation, though clinical translation ultimately proved unsuccessful
Its worth noting that over 10% of patients may pause or stop treatment due to side effects, emphasizing the need for tailored medical approaches
CM contributed to the design of the study, construction of the model, interpretation of the data, and revision of the manuscript
Out of all patients with an overweight or obesity diagnosis who were prescribed a GLP-1 drug, the percentage of patients who had behavioural health services related to their condition declined from 2019 to 2024
A Review of the Clinical and Epidemiologic Evidence Relevant to the Impact of Postdiagnosis Isoflavone Intake on Breast Cancer Outcomes
Wysham CH, Pilon D, Ingham M, et al